Adalvo is pleased to announce the successful DCP filing on its Teriflunomide development, a new addition to our high-value product portfolio offering to our partners.
Our product, Teriflunomide 14mg film-coated tablets, is a fully bioequivalent version of Aubagio® 14mg film-coated tablets that has been co-developed in collaboration with one of our strategic partners.
Aubagio® is a blockbuster specialty drug and is indicated for the treatment of relapsing remitting multiple sclerosis. The brand is currently selling $2.4 billion globally as reported by IQVIA.
We have filed our DCP on Day-1 after expiry of Data Exclusivity and we are aiming to be one of the first companies launching this affordable medicine for patients globally.
Leveraging on Teriflunomide we further pave the road for our highly distinguished CNS portfolio that already includes many high-value, complex and differentiated assets.